• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >Multiparametric MRI for prostate cancer diagnosis: current status and future directions
【24h】

Multiparametric MRI for prostate cancer diagnosis: current status and future directions

机译：用于前列腺癌诊断的多次MRI：现状和未来方向

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.
机译：前列腺癌的目前诊断途径导致过度诊断和随后的过度治疗以及许多男性的未被指令和错过诊断。 前列腺的Multiparametric MRI（MPMRI）已被确定为可以减轻这些诊断错误的测试。 MPMRI的性能可以根据所研究的群体而变化，MRI本身的执行，放射科学家的经验是考虑另外的生物标志物，是否单独进行，或者除系统活检外是否进行MPMRI靶向活检。 实施的许多挑战仍然存在，例如确保MPMRI的高质量执行和报告，并确保该诊断途径具有成本效益。 尽管如此，新兴临床试验数据支持采用这项技术，作为诊断前列腺癌的护理标准的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号